Assets
Crypto Deposit
Fiat Deposit
Convert
Transfer
Withdraw
My vouchers
Fund history
Dashboard
Account Security
Identity verification
API Management
Transaction Report
Log out
Register
BTCC / BTCC Square / Global Cryptocurrency /
Eli Lilly’s $3B China Bet on Oral Weight-Loss Pill

Eli Lilly’s $3B China Bet on Oral Weight-Loss Pill

Author:
Global Cryptocurrency
Published:
2026-03-11 12:24:26
16
3
BTCCSquare news:

Eli Lilly commits $3 billion to expand production capacity in China for orforglipron, its experimental once-daily oral GLP-1 agonist targeting obesity and type-2 diabetes. The move comes as the drugmaker awaits regulatory approval in China, having filed its marketing application in late 2025.

Bernstein maintains bullish sentiment with a $1,300 price target (30% upside from current ~$1,008), citing orforglipron's 12.4% average weight loss in trials and seamless transition potential from injectables like Zepbound. Lilly's new employer-focused LillyConnect platform further expands market access through partnerships with GoodRx and Cost Plus Drugs.

|Square

Get the BTCC app to start your crypto journey

Download on the App Store GEI IT ON Google Play

Get started today Scan to join our 100M+ users

Exchange for a better future

Products
Services
Guides
About Us
Terms & Agreement
Customer Service

Risk warning: Digital asset trading is an emerging industry with bright prospects, but it also comes with huge risks as it is a new market. The risk is especially high in leveraged trading since leverage magnifies profits and amplifies risks at the same time. Please make sure you have a thorough understanding of the industry, the leveraged trading models, and the rules of trading before opening a position. Additionally, we strongly recommend that you identify your risk tolerance and only accept the risks you are willing to take. All trading involves risks, so you must be cautious when entering the market.

The world’s longest-running cryptocurrency exchange since 2011 © 2011 - 2026 BTCC.com. All rights reserved

All articles reposted on this platform are sourced from public networks and are intended solely for the purpose of disseminating industry information. They do not represent any official stance of BTCC. All intellectual property rights belong to their original authors. If you believe any content infringes upon your rights or is suspected of copyright violation, please contact us at [email protected]. We will address the matter promptly and in accordance with applicable laws.BTCC makes no explicit or implied warranties regarding the accuracy, timeliness, or completeness of the republished information and assumes no direct or indirect liability for any consequences arising from reliance on such content. All materials are provided for industry research reference only and shall not be construed as investment, legal, or business advice. BTCC bears no legal responsibility for any actions taken based on the content provided herein.